Search Results - "Aljubran, Ali Husain"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Pattern of use of positron emission tomography/computed tomography scan in non-colorectal gastrointestinal cancers at KFSHRC, Riyadh, Saudi Arabia by Aljubran, Ali Husain, Badran, Ahmed, Alshaer, Omar, Alhashem, Hashem, Omar, Aymen, Eldali, Abdelmoniem

    “…Background Positron emission tomography/computed tomography (PET/CT) scan is useful if clinically indicated. It is not for conventional routine use due to its…”
    Get full text
    Journal Article
  2. 2

    Response rate and survival for patients with metastatic colorectal cancer from right-sided versus left-sided tumors, treated with first-line triplet chemotherapy with bevacizumab by Bazarbashi, Shouki, Omar, Ayman, Aljubran, Ali Husain, Alzahrani, Ahmed M

    Published in Journal of clinical oncology (01-02-2017)
    “…Abstract only 801 Background: Recent data have shown that right sided colonic cancer represent a molecularly different class of tumors from the left sided ones…”
    Get full text
    Journal Article
  3. 3

    Treatment of neuroendocrine tumors (NETs) with combination of everolimus and lu-177 radiolabeled somatostatin analogue by Aljubran, Ali Husain, Tuli, Mahmoud, Raef, Hussein

    Published in Journal of clinical oncology (20-01-2015)
    “…Abstract only TPS502 Background: Treatment of Grade 1 and 2 NET is complex and involves surgical, Locoregional and systemic modalities depending on the…”
    Get full text
    Journal Article
  4. 4

    Combination of everolimus and lu-177 PRRT in treatment of G1-2 neuroendocrine tumors (NET): Phase 1-2 study by Aljubran, Ali Husain, Alrowaili, Mohamed, Raef, Hussein, Bazarbashi, Shouki, Alzahrani, Ahmed M, Almuhaideb, Ahmed, Almanea, Hadeel, Badran, Ahmed ali, Al-Dalee, Abdelmuniem, Tuli, Mahmoud

    Published in Journal of clinical oncology (01-02-2019)
    “…Abstract only 386 Background: Everolimus and Lutetium-177 PRRT were approved as monotherapy. However, animal model research showed synergistic effect of the…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Pattern of use of complementary alternative medicine (CAM) among cancer patients in Saudi Arabia by Al-Dalee, Abdelmuniem, Aljubran, Ali Husain

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only e19525 Background: Use of complementary alternative medicine CAM is prevalent among cancer patients in Saudi Arabia. However, there is yet no…”
    Get full text
    Journal Article
  7. 7

    Outcome of use of regorafenib in metastatic colorectal cancer in routine clinic practice in Saudi Arabia by Aljubran, Ali Husain, Zahir, Muhammad, Gad, Ahmed, Al-Dalee, Abdelmuniem, Bazarbashi, Shouki, Elshenawy, Mahmoud Abdelsatar, Al Zahrani, Ahmad

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only e15021 Background: Regorafenib is a multi-kinase inhibitor that was FDA approved for the treatment of refractory advanced colorectal cancer. It…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Perception and reaction of cancer patients to the diagnosis of cancer and their attitude towards disclosure of diagnosis: Local perspective from Saudi Arabia by Aljubran, Ali Husain, Kandasamy, Ravichandran, Al-Dalee, Abdelmuniem

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only e19524 Background: Understanding the attitudes of cancer patients towards different cancer related issues is important for care delivery…”
    Get full text
    Journal Article
  10. 10

    Assessment of cancer patients of the local patient’s support organizations and the available sources of the patient’s health education: Local perspectives from Saudi Arabia by Kandasamy, Ravichandran, Al-Dalee, Abdelmuniem, Aljubran, Ali Husain

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only e19526 Background: Few Local patients’ support organizations are available for cancer patients in Saudi Arabia. These non governmental…”
    Get full text
    Journal Article